Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of two antiretroviral combinations for HIV-1 post-exposure prophylaxis
2011-002069-39Phase 4Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jul 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir disoproxil fumarate, emtricitabine, lopinavir, ritonavir and maraviroc in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Discontinuation of initial HIV post-exposure prophylaxis. Started Jul 2011; status: completed.
02
Drugs
tenofovir disoproxil fumarateemtricitabinelopinavirritonavirmaraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2011-002069-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002069-39.